Clinical trial results:
A Comparative Study of Olopatadine Hydrochloride Ophthalmic Solution 0.2% QD vs Olopatadine Hydrochloride Ophthalmic Solution 0.1% BID in the Treatment of Allergic Conjunctivitis in Chinese Subjects

Summary

EudraCT number	2016-004317-27
Trial protocol	Outside EU/EEA
Global end of trial date	15 October 2015

Results information

Result version number	v1 (current)
This version publication date	15 September 2017
First version publication date	15 September 2017

Trial information

Trial identification

Sponsor protocol code	C-12-010

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02322216
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Novartis Pharmaceuticals
Sponsor organisation address	Park View, Riverside way, Watchmoor Park, Camberley , Surrey, United Kingdom, GU15 3YL
Public contact	Dennis Wong, Novartis Pharmaceuticals, dennis.wong@novartis.com
Scientific contact	Dennis Wong, Novartis Pharmaceuticals, dennis.wong@novartis.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	15 October 2015
Is this the analysis of the primary completion data?	Yes
Primary completion date	15 October 2015
Global end of trial reached?	Yes
Global end of trial date	15 October 2015
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The purpose of this study is to evaluate olopatadine 0.2% QD (once per day) compared to olopatadine 0.1% BID (twice per day) in the treatment of ocular itching associated with allergic conjunctivitis.

Protection of trial subjects:

Prior to the start of the study, the study protocol, the informed consent and assent documents, patient instruction sheets, the Investigator's Brochure, as well as any advertising materials used to recruit patients were submitted to institutional review boards (IRBs) and independent ethics committees (IECs). The IRB/IECs reviewed all documents and approved required documents; copies of the approval letters were provided to Alcon. Consistent with both the IRB/IEC's requirements and all applicable regulations, the Investigators periodically provided study updates to the IRB/IEC. A patient or parent/legal guardian (if necessary, a legally authorized representative) provided informed consent, and children signed an approved assent form when appropriate. This study was conducted in accordance with Good Clinical Practices (GCP) and the ethical principles that have their origins in the Declaration of Helsinki.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	30 December 2014
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	China: 252
Worldwide total number of subjects	252
EEA total number of subjects	0

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	17
Adolescents (12-17 years)	11

Adults (18-64 years)	218
From 65 to 84 years	6
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Participants were recruited from 10 study centers located in China.

Pre-assignment

Screening details:

Of the 383 subjects who signed an informed consent form, 130 were exited as screen failures prior to randomization and 253 were randomized. This reporting group includes all randomized and treated subjects (252).

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Single blind
Roles blinded	Investigator[1]

Arms

Are arms mutually exclusive?	Yes
Arm title	PATADAY

Arm description:

Olopatadine hydrochloride ophthalmic solution 0.2% in the morning and olopatadine 0.2% Vehicle in the evening, 1 drop in each eye for 14 days

Arm type	Experimental
Investigational medicinal product name	Olopatadine Hydrochloride Ophthalmic Solution 0.2%
Investigational medicinal product code	EXZ829B
Other name	PATADAY®
Pharmaceutical forms	Eye drops, solution
Routes of administration	Ocular use

Dosage and administration details:

Olopatadine hydrochloride ophthalmic solution 0.2% in the morning, 1 drop in each eye for 14 days

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Eye drops, solution
Routes of administration	Ocular use

Dosage and administration details:

Olopatadine 0.2% vehicle in the evening, 1 drop in each eye for 14 days

Arm title	PATANOL

Arm description:

Olopatadine hydrochloride ophthalmic solution 0.1%, 1 drop in each eye in the morning and evening, for 14 days

Arm type	Active comparator
Investigational medicinal product name	Olopatadine Hydrochloride Ophthalmic Solution 0.1%
Investigational medicinal product code	
Other name	PATANOL®
Pharmaceutical forms	Eye drops, solution
Routes of administration	Ocular use

Dosage and administration details:

Olopatadine hydrochloride ophthalmic solution 0.1%, 1 drop in each eye in the morning and evening, for 14 days

Notes:
[1] - The roles blinded appear inconsistent with a simple blinded trial.
Justification: This was a single-blind trial and only the investigator was masked.

Number of subjects in period 1	PATADAY	PATANOL
Started	126	126
Completed	124	123
Not completed	2	3
Consent withdrawn by subject	1	3
Adverse event, non-fatal	1	-

Baseline characteristics

Reporting groups	
Reporting group title	PATADAY
Reporting group description:	
Olopatadine hydrochloride ophthalmic solution 0.2% in the morning and olopatadine 0.2% Vehicle in the evening, 1 drop in each eye for 14 days	
Reporting group title	PATANOL
Reporting group description:	
Olopatadine hydrochloride ophthalmic solution 0.1%, 1 drop in each eye in the morning and evening, for 14 days	

Reporting group values	PATADAY	PATANOL	Total
Number of subjects	126	126	252
Age categorical Units: Subjects			
10-17 years	14	14	28
18-64 years	109	109	218
≥65 years	3	3	6
Gender categorical			
This analysis population includes all subjects who received study drug (Safety Analysis Set).			
Units: Subjects			
Female	83	88	171
Male	43	38	81

End points

End points reporting groups

Reporting group title	PATADAY
Reporting group description:	
Olopatadine hydrochloride ophthalmic solution 0.2% in the morning and olopatadine 0.2% Vehicle in the evening, 1 drop in each eye for 14 days	
Reporting group title	PATANOL
Reporting group description:	
Olopatadine hydrochloride ophthalmic solution 0.1%, 1 drop in each eye in the morning and evening, for 14 days	

Primary: Change From Baseline in Worst Ocular Itching Score During the 24 Hours Prior at Day 14

End point title	Change From Baseline in Worst Ocular Itching Score During the 24 Hours Prior at Day 14
End point description:	
Severity of ocular itching was evaluated as the worst score observed in the past 24 hours prior to each study visit. Ocular itching was assessed by the participant on a scale from 0-4, where 0=None and 4=Incapacitating itch. One eye (study eye) contributed to the analysis. This analysis population includes the Per Protocol Set with non-missing data.	
End point type	Primary
End point timeframe:	
Baseline, Day 14	

End point values	PATADAY	PATANOL		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	118	112		
Units: Units on a scale				
arithmetic mean (standard error)	-2.57 (± 0.09)	-2.62 (± 0.092)		

Statistical analyses

Statistical analysis title	Change from baseline in mean itching score
Statistical analysis description:	
Treatment difference in mean itching score (worst itching score during 24 hours) change from baseline at Day 14	
Comparison groups	PATADAY v PATANOL

Number of subjects included in analysis	230
Analysis specification	Pre-specified
Analysis type	non-inferiority
Parameter estimate	Mean difference (final values)
Point estimate	0.05
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.17
upper limit	0.26

Adverse events

Adverse events information[1]

Timeframe for reporting adverse events:

Adverse events (AEs) were collected from the time of informed consent and for the duration of participation in the study (2 weeks). This analysis group includes all participants who received study treatment.

Adverse event reporting additional description:

An AE is defined as any untoward medical occurrence in a subject who is administered a study treatment regardless of whether or not the event has a causal relationship with the treatment. Reports of AEs were obtained through solicited and spontaneous comments from the participants.

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	17.0

Reporting groups

Reporting group title	PATADAY

Reporting group description:

All subjects treated with olopatadine hydrochloride ophthalmic solution 0.2%

Reporting group title	PATANOL

Reporting group description:

All subjects treated with olopatadine hydrochloride ophthalmic solution 0.1%

Serious adverse events	PATADAY	PATANOL	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 126 (0.00%)	0 / 126 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events			

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	PATADAY	PATANOL	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	0 / 126 (0.00%)	0 / 126 (0.00%)	

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.
Justification: No non-serious adverse events occurred above the 5% threshold.

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported